Literature DB >> 33346094

LncRNA CASC9 promotes proliferation, migration and inhibits apoptosis of hepatocellular carcinoma cells by down-regulating miR-424-5p.

Jingjing Yao1, Jindong Fu1, Ying Liu2, Wei Qu1, Guangdong Wang1, Zaojun Yan3.   

Abstract

INTRODUCTION AND
OBJECTIVES: CASC9 and miR-424-5p are closely related with hepatocellular carcinoma (HCC) progression. This study aimed to evaluate the effect of CASC9 involved with miR-424-5p on the development of HCC.
MATERIALS AND METHODS: qRT-PCR was performed to determine the mRNA expressions of CASC9 and miR-424-5p in HCC tissues/cells and adjacent normal tissues/human hepatic epithelial cells, and to analyze the relationship of CASC9 with the clinico-pathological characteristics and prognosis of HCC patients. Then, cell proliferation was measured by CCK-8 and1 clone formation assays. Apoptosis of HCC cells was measured by flow cytometry. Besides, cell migration and invasion were determined by scratch wound-healing and Transwell assays, respectively. DIANA-LncBase V2 and dual luciferase reporter gene assay were used to verify the targeted relationship between CASC9 and miR-424-5p. Bcl-2, Bax and cleaved caspase-3 expressions were detected by Western blot.
RESULTS: Higher expression of CASC9 was observed in HCC tissues/ cells than in adjacent normal tissues/ human hepatic epithelial cells, and was closely linked to poor prognosis of HCC, tumor size, TNM stage, differentiation degree, lymph node metastasis and alpha-fetoprotein (AFP). Down-regulation of CASC9 decreased the proliferation, invasion and migration of HCC cells while enhancing apoptosis. Besides, CASC9 was negatively correlated with miR-424-5p. MiR-424-5p inhibitor enhanced cell proliferation, invasion and migration while decreasing apoptosis. Interestingly, siRNA-CASC9 partially offset the effects of miR-424-5p inhibitor on HCC cells.
CONCLUSION: CASC9 promoted proliferation, invasion and migration and inhibited apoptosis in HCC cells by inhibiting miR-424-5p.
Copyright © 2020 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Apoptosis; CASC9; Hepatocellular carcinoma; Migration; Proliferation; miR-424-5p

Mesh:

Substances:

Year:  2020        PMID: 33346094     DOI: 10.1016/j.aohep.2020.100297

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  6 in total

1.  Changes and Prognostic Value of lncRNA CASC9 in Patients with Advanced Colon Cancer after Chemotherapy.

Authors:  Yingwei Jiao; Qiang Liu; Hongbo Zhao; Xianzhen Hu; Jinlong Sun; Xiaohong Liu
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-18       Impact factor: 2.629

Review 2.  Sequence Requirements for miR-424-5p Regulating and Function in Cancers.

Authors:  Jiangying Xuan; Yingxia Liu; Xiaoping Zeng; Hongmei Wang
Journal:  Int J Mol Sci       Date:  2022-04-06       Impact factor: 5.923

3.  The Clinical Value of Long Noncoding RNA DDX11-AS1 as a Biomarker for the Diagnosis and Prognosis of Hepatocellular Carcinoma.

Authors:  Xiaojun Luo; Yang Wang; Xi Zhang; Wenbin Liu
Journal:  J Oncol       Date:  2022-08-29       Impact factor: 4.501

4.  Assessment of circulating levels of microRNA-326, microRNA-424, and microRNA-511 as biomarkers for hepatocellular carcinoma in Egyptians.

Authors:  Samar Samir Youssef; Asmaa Elfiky; Mohamed M Nabeel; Hend Ibrahim Shousha; Tamer Elbaz; Dalia Omran; Mohammad Saeed Marie; Mohammad A Elzahry; Amr Abul-Fotouh; Ahmed Hashem; Mohamed F Guda; Ashraf O Abdelaziz
Journal:  World J Hepatol       Date:  2022-08-27

5.  [MicroRNA-424 inhibits autophagy and proliferation of hepatocellular carcinoma cells by targeting ATG14].

Authors:  Z Zhao; W Huang; J He; C Feng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-07-20

6.  Liver-specific LINC01146, a promising prognostic indicator, inhibits the malignant phenotype of hepatocellular carcinoma cells both in vitro and in vivo.

Authors:  Xiaoyun Ma; Meile Mo; Chao Tan; Jennifer Hui Juan Tan; Huishen Huang; Bihu Liu; Dongping Huang; Shun Liu; Xiaoyun Zeng; Xiaoqiang Qiu
Journal:  J Transl Med       Date:  2022-01-31       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.